Health & Food
FDA advisers want new labels for osteoporosis drug
TRENTON, N.J. (KABC) -- Food and Drug Administration advisers are calling for revised labels for osteoporosis drugs.
They want makers of widely used osteoporosis medicines to clarify how long patients should take them for the greatest benefit and least risk.
The FDA itself will decide later what the new labels should say for each of the drugs: Fosamax, Boniva, Actonel, Atelvia and Reclast.
A few patients have suffered serious complications, including jawbone destruction and unusual thighbone fractures, generally after several years of taking the medicines.
The drugs stop and reverse dangerous thinning of bones in many people, preventing much more common hip and spine fractures that cause pain and can result in hospitalizations, nursing home stays and early death.
But after several years, it's unclear whether the drugs, a class called bisphosphonates, do more harm than good.
More than 10 million Americans, mostly women over age 50, have osteoporosis, and 34 million more have low bone mass that could lead to osteoporosis, in which the body breaks down bone tissue faster than it rebuilds it.
The Associated Press contributed to this report.
health, fda, health & food
- Storm moves out of SoCal; cold air remains
- OC crash kills 4; alcohol, speed suspected
- US vet Merrill Newman back in CA from NKorea
- Fire hits Loyola Marymount University dorm
- Large sinkhole closes Woodland Hills road
- 87-year-old rescued from OC mobile home fire
- Salvation Army bell-ringer breaks record in IE
- Mandela's family: 'We have lost a great man'
- Pearl Harbor ceremony marks attack anniversary
- abcnews: Alleged cannibal ran hotel w/ grill area
- Stanford beats ASU 38-14 in Pac-12 title game
- Auction features items from Nancy Drew author
- Photos: Jennifer Lopez at March of Dimes event